Gildeuretinol Acetate versus Placebo for Geographic Atrophy Secondary to Age-Related Macular Degeneration
Open Access
- 4 June 2026
- journal article
- Published by Elsevier in Ophthalmology Retina
- Vol. 10 (10) , 1027-1035
Abstract
No abstract availableKeywords
Funding Information
- National Eye Institute
This publication has 21 references indexed in Scilit:
- Visual Acuity and Quality of Life Outcomes With Pegcetacoplan Treatment: A Post Hoc Analysis From the OAKS and DERBY TrialsAmerican Journal of Ophthalmology, 2025
- Pegcetacoplan for the treatment of geographic atrophy secondary to age-related macular degeneration (OAKS and DERBY): two multicentre, randomised, double-masked, sham-controlled, phase 3 trialsThe Lancet, 2023
- Efficacy and safety of avacincaptad pegol in patients with geographic atrophy (GATHER2): 12-month results from a randomised, double-masked, phase 3 trialThe Lancet, 2023
- Avacincaptad pegol for geographic atrophy secondary to age-related macular degeneration: 18-month findings from the GATHER1 trialEye, 2023
- Vitamin A cycle byproducts impede dark adaptationJournal of Biological Chemistry, 2021
- Reliability and Convergent Validity of The Nei Vfq-25 with and Without Near and Distance Activity Appendix Items In Patients with Geographic Atrophy (GA) Secondary to Age Related Macular Degeneration (AMD)Value in Health, 2016
- Rescue of the Stargardt phenotype in Abca4 knockout mice through inhibition of vitamin A dimerizationProceedings of the National Academy of Sciences, 2015
- Visual Acuity as an Outcome Measure in Clinical Trials of Retinal DiseasesOphthalmology, 2007
- Responsiveness of the National Eye Institute Visual Function Questionnaire to Progression to Advanced Age-Related Macular Degeneration, Vision Loss, and Lens OpacityArchives of Ophthalmology (1950), 2005
- Visual Function Abnormalities and Prognosis in Eyes with Age-related Geographic Atrophy of the Macula and Good Visual AcuityOphthalmology, 1997